版本:
中国

BRIEF-Chemocentryx says Avacopan safe and well tolerated at ERA-EDTA congress

June 6 Chemocentryx Inc

* Oral presentations at ERA-EDTA congress highlight fourth potential indication for Avacopan and potential for CCR2 inhibition in focal segmental glomerulosclerosis (FSGS)

* Chemocentryx Inc says Avacopan appeared to be safe and well tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐